Novartis receives EU approval for Rasilamlo®, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
http://insciences.org/article.php?article_id=10079
Rasilamlo has been evaluated in clinical studies involving more than 5,000 patients with mild-to-severe high blood pressure. Data shows that Rasilamlo provides greater blood pressure reductions than Rasilez and amlodipine alone.
http://insciences.org/article.php?article_id=10079
Rasilamlo has been evaluated in clinical studies involving more than 5,000 patients with mild-to-severe high blood pressure. Data shows that Rasilamlo provides greater blood pressure reductions than Rasilez and amlodipine alone.
